iOnctura SA bags €15m in Series A round

The Series A round was led by Dutch investor INKEF Capital, and Swiss VI Partners  AG and Zurich-based investor Schroder Adveq as new co-investors. Existing investors M Ventures also participated in the round aimed at bringing the two programmes to the clinic within the next 12 months.

iOnctura SA’s PI3K? blocker IOA-244 is designed to help patients with immunosuppressive tumour microenvironment to inhibit regulatory T cell (Treg) activity in order to boost efficacy of checkpoint inhibitors of chemotherapeutics while preventing liver toxicity and side effects observed with approved PI3K? inhibitors such as Gilead Science’s blood cancer drug idelalisib and non-selective PI3K blockers such as duvelisib (Verastem Inc.) or, copanlisib (Bayer AG).

The autotaxin blocker IOA-289, which was licenced from Cancer Research UK, is a pulmonary fibrosis inhibitorand cancer drug, which will be targeted against pancreatic cancer first.